1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Recovery ‘Will Take Time’ For Nichi-Iko As Operating Profit Falls 99.8%

Japanese Firm Slashes Profit Expectations On Back Of Q3 Results

 
• By Dean Rudge

Nichi-Iko has a full menu of problems affecting operations both in its native Japan and US Sagent business. These compounded to devastate the firm’s bottom line in the nine months to 31 December, the firm’s financial results have revealed.

Japanese flag
Nichi-Iko reported a group operating profit of just ¥17m for the nine months ended 31 December • Source: Shutterstock

A “full-on recovery will take time” for Japan’s Nichi-Iko Pharmaceutical Co., Ltd., considering a variety of company-specific issues currently facing the firm, as Nichi-Iko reported a near 100% drop in its operating profit for the nine months ended 31 December 2020.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 
• By Urtė Fultinavičiūtė

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

Teva Crib Sheet Reveals Uzedy, Lenalidomide Expectations Ahead Of Q1

 
• By Dean Rudge

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.

Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024

 
• By Dave Wallace

With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.

Henlius Builds Profitability Streak With Second Year In The Black

 
• By Adam Zamecnik

The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.

More from Business

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

Fresenius Divests Brazilian Sites To EMS Amid Structural Streamlining

 
• By Adam Zamecnik

The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.

Aurobindo Plots Rivaroxaban Roll-Out As FDA Approves 2.5mg Strength ANDA

 
• By Dean Rudge

Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.